Neumora Therapeutics is projected to report a Q2 2026 consensus revenue of $0.00 and an EPS loss of -$0.24, with its current price of $1.59 trading significantly below the average analyst target of $6.57.
Investors are primarily focused on the company's strategic pipeline pivot and leadership transition following the discontinuation of its lead depression candidate, navacaprant, in June 2026.
The company has shifted its clinical focus toward NMRA-511 for Alzheimer’s agitation and the newly prioritized NMRA-215 for obesity treatment. Updated guidance on the cash runway, currently projected to last into late 2027, remains a critical metric as newly appointed CEO Joshua Pinto takes the helm to navigate the firm's restructuring.